RT Journal Article
T1 Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study
A1 Perez-Recio, Sandra
A1 Pallares, Natalia
A1 Grijota-Camino, Maria D.
A1 Sanchez-Montalva, Adrian
A1 Barcia, Laura
A1 Campos-Gutierrez, Silvia
A1 Pomar, Virginia
A1 Rabunal-Rey, Ramon
A1 Balcells, Maria Elvira
A1 Gazel, Deniz
A1 Montiel, Natalia
A1 Vicente, Diego
A1 Goic-Barisic, Ivana
A1 Schon, Thomas
A1 Paues, Jakob
A1 Marekovic, Ivana
A1 Cacho-Calvo, Juana
A1 Barac, Aleksandra
A1 Goletti, Delia
A1 Garcia-Gasalla, Mercedes
A1 Maria Barcala, Jose
A1 Teresa Tortola, Maria
A1 Anibarro, Luis
A1 Suarez-Toste, Isabel
A1 Moga, Esther
A1 Gude-Gonzalez, Maria J.
A1 Naves, Rodrigo
A1 Karsligil, Tekin
A1 Martin-Penaranda, Tania
A1 Stevanovic, Goran
A1 Trigo, Matilde
A1 Rubio, Veronica
A1 Karaoglan, Ilkay
A1 Bayram, Nazan
A1 Alcaide, Fernando
A1 Tebe, Cristian
A1 Santin, Miguel
A1 Spanish Soc Clinical Microbiology, 
K1 QuantiFERON-TB gold plus
K1 diagnosis
K1 latent tuberculosis infection
K1 tuberculosis-specific CD8 T cells
K1 Gamma release assays
K1 Active tuberculosis
K1 Predictive-value
K1 Cell responses
K1 Cd4
K1 Contacts
K1 Antigen
AB We investigated whether the difference of antigen tube 2 (TB2) minus antigen tube 1 (TB1) (TB22TB1) of the QuantiFERON-TB gold plus test, which has been postulated as a surrogate for the CD81 T-cell response, could be useful in identifying recent tuberculosis (TB) exposure. We looked at the interferon gamma (IFN-g) responses and differences in TB2 and TB1 tubes for 686 adults with QFT-plus positive test results. These results were compared among groups with high (368 TB contacts), low (229 patients with immune-mediated inflammatory diseases [IMID]), and indeterminate (89 asylum seekers or people from abroad [ASPFA]) risks of recent TB exposure. A TB2-TB1 value.0.6 IU.ml(-1) was deemed to indicate a true difference between tubes. In the whole cohort, 13.6%, 10.9%, and 11.2% of cases had a TB2>TB1 result in the contact, IMID, and ASPFA groups, respectively (P = 0.591). The adjusted odds ratios (aORs) for an association between a TB2-TB1 result of >0.6 IU.ml(-1) and risk of recent exposure versus contacts were 0.71 (95% confidence interval [CI], 0.31 to 1.61) for the IMID group and 0.86 (95% CI, 0.49 to 1.52) for the ASPFA group. In TB contact subgroups, 11.4%, 15.4%, and 17.7% with close, frequent, and sporadic contact had a TB2>TB1 result (P = 0.362). The aORs versus the close subgroup were 1.29 (95% CI, 0.63 to 2.62) for the frequent subgroup and 1.55 (95% CI, 0.67 to 3.60) for the sporadic subgroup. A TB2-TB1 difference of.0.6 IU.ml(-1) was not associated with increased risk of recent TB exposure, which puts into question the clinical potential as a proxy marker for recently acquired TB infection.IMPORTANCE Contact tuberculosis tracing is essential to identify recently infected people, who therefore merit preventive treatment. However, there are no diagnostic tests that can determine whether the infection is a result of a recent exposure or not. It has been suggested that by using the QuantiFERON-TB gold plus, an interferon gamma (IFN-gamma) release assay, a difference in IFN-gamma production between the two antigen tubes (TB2 minus TB1) of.0.6 IU.ml(-1) could serve as a proxy marker for recent infection. In this large multinational study, infected individuals could not be classified according to the risk of recent exposure based on differences in IFN- g in TB1 and TB2 tubes that were higher than 0.6 IU.ml(-1). QuantiFERON-TB gold plus is not able to distinguish between recent and remotely acquired tuberculosis infection, and it should not be used for that purpose in contact tuberculosis tracing.
PB Amer soc microbiology
SN 2165-0497
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/25090
UL https://hdl.handle.net/10668/25090
LA en
DS RISalud
RD Apr 4, 2025